Docetaxel vs Ixabepilone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Microtubules (tubulin) · full HR+/HER2- Metastatic Breast Cancer pipeline
Docetaxel · Taxotere
Marketed by Sanofi
NCT00002662 · Phase 3 · completed
The study used randomization and an active treatment comparator, but it was open-label and the registry does not report its sample size, primary endpoint, or results. Without posted outcome data, the trial provides only limited evidence about the comparative effects of docetaxel and paclitaxel.
Next expected readout: December 2026 · NCT04140526 (registry estimate)
Reported efficacy
ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. (missed)
Result source: NCT00002662
Ixabepilone
Marketed by R-Pharm
NCT00080301 · Phase 3 · completed
The trial randomized 752 participants to ixabepilone plus capecitabine or capecitabine alone and used progression-free survival, a hard clinical endpoint, as its primary outcome. The primary comparison favored the combination, but the study was open-label rather than double-blind; overall survival, a secondary endpoint, was not significantly improved.
Reported efficacy
Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) (based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity): Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) (based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity): Ixabepilone + Capecitabine 5.85 Months (95% CI 5.45 to 6.97) | Capecitabine 4.17 Months (95% CI 3.81 to 4.5) (met)
Result source: NCT00080301
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Docetaxel | Ixabepilone |
|---|---|---|
| PFS, median | 9.5 vs 8.2+1.3 vs placeboNCT0070332610 other results
| —Not reported |
| OS, median | 30.3 vs 28.7+1.6 vs placeboNCT007033266 other results
| —Not reported |
| ORR | 44.7% vs 37.9%+6.8 vs placeboNCT007033265 other results
| —Not reported |
| Clinical benefit rate | 60.4% vs 62%vs TrastuzumabNCT006672512 other results
| —Not reported |
PFS, median
- Docetaxel
- 9.5 vs 8.2+1.3 vs placeboNCT00703326
10 other results
- 8.7 vs 8 NCT00333775
- 8.8 vs 8 NCT00333775
- 11.7 vs 10.6 NCT03084237
- 8.9 vs 9.0 NCT00191152
- 4.5 vs 2.3 NCT00191152
- 20.7 NCT01572038
- 6.6 vs 3.8 NCT00179309
- 23 NCT02445586
- 12.4 NCT01446016
- 8.4 NCT00054275
- Ixabepilone
- —Not reported
OS, median
- Docetaxel
- 30.3 vs 28.7+1.6 vs placeboNCT00703326
6 other results
- 30 vs 38.3 NCT00667251
- 30 NCT00667251
- 23.3 vs 23.0 NCT00191152
- 65.3 NCT01572038
- 25.4 NCT01446016
- 22.3 NCT00054275
- Ixabepilone
- —Not reported
ORR
- Docetaxel
- 44.7% vs 37.9%+6.8 vs placeboNCT00703326
5 other results
- 88.6% vs 78.2% NCT02586025
- 64.2% vs 63.3% NCT00667251
- 66.7% vs 67.4% NCT00667251
- 79.5% NCT01572038
- 45.2% NCT01446016
- Ixabepilone
- —Not reported
Clinical benefit rate
- Docetaxel
- 60.4% vs 62%vs TrastuzumabNCT00667251
2 other results
- 61.1% vs 65.2% NCT00667251
- 86.2% NCT01572038
- Ixabepilone
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ixabepilone: registry results are on file for HR+/HER2- Metastatic Breast Cancer, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Docetaxel: 4 of 4 rows · Ixabepilone: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Docetaxel |
|---|---|
| Dropout rate | 8.6%Trastuzumab With AC-TH Regimena NCT02419742 · Phase 4 · registry result, not featured evidence · combination show 31 more results3.8%Trastuzumab With TCH Regimen NCT02419742 · Phase 4 · registry result, not featured evidence · combination 75% NCT02445586 · Phase 4 · registry result, not featured evidence · combination n/a: no completion milestoneLapatinib (LTax/L) NCT00667251 · Phase 3 · registry result, not featured evidence —Lapatinib (LTax/L) - All Participa NCT00667251 · Phase 3 · registry result, not featured evidence 5% NCT02586025 · Phase 3 · registry result, not featured evidence 52.3% NCT03084237 · Phase 3 · registry result, not featured evidence · combination 13.4% NCT00703326 · Phase 3 · registry result, not featured evidence · combination 69% NCT01572038 · Phase 3 · registry result, not featured evidence · combination 18.6% NCT02953340 · Phase 3 · registry result, not featured evidence · combination — NCT02643420 · Phase 3 · registry result, not featured evidence · combination 11.1%Trastuzumab (AryoTrust) NCT03425656 · Phase 3 · registry result, not featured evidence —Trastuzumab (AryoTrust) / ACTH NCT03425656 · Phase 3 · registry result, not featured evidence · combination — NCT02472964 · Phase 3 · registry result, not featured evidence · combination 15.1%Trastuzumab (SID) NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (SID) Adjuvant NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (SID) Neoadjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 17.4%Trastuzumab (Vial) NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (Vial): Adjuvant NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (Vial): Neoadjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 25.1%AC Followed by Docetaxel + Hercept NCT00021255 · Phase 3 · registry result, not featured evidence · combination 13.9%Docetaxel + Carboplatin + Hercepti NCT00021255 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneDocetaxel 100 mg/m^2 Plus Bevacizu NCT00333775 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneDocetaxel 100 mg/m^2 Plus Bevacizu NCT00333775 · Phase 3 · registry result, not featured evidence · combination 64.8% NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 20.6%Cohort A: ddAC, Paclitaxel, Pertuz NCT02132949 · Phase 2 · registry result, not featured evidence · combination 13.9%Cohort B: FEC, Docetaxel, Pertuzum NCT02132949 · Phase 2 · registry result, not featured evidence · combination 18.4% NCT01446016 · Phase 2 · registry result, not featured evidence · combination — NCT01527487 · Phase 2 · registry result, not featured evidence · combination — NCT00068341 · Phase 2 · registry result, not featured evidence · combination 16% NCT00179309 · Phase 2 · registry result, not featured evidence · combination 28.2% NCT00054275 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.4%Trastuzumab With AC-TH Regimena NCT02419742 · Phase 4 · registry result, not featured evidence · combination show 31 more results0%Trastuzumab With TCH Regimen NCT02419742 · Phase 4 · registry result, not featured evidence · combination — NCT02445586 · Phase 4 · registry result, not featured evidence · combination —Lapatinib (LTax/L) NCT00667251 · Phase 3 · registry result, not featured evidence —Lapatinib (LTax/L) - All Participa NCT00667251 · Phase 3 · registry result, not featured evidence 0.5% NCT02586025 · Phase 3 · registry result, not featured evidence — NCT03084237 · Phase 3 · registry result, not featured evidence · combination 0.1% NCT00703326 · Phase 3 · registry result, not featured evidence · combination — NCT01572038 · Phase 3 · registry result, not featured evidence · combination — NCT02953340 · Phase 3 · registry result, not featured evidence · combination — NCT02643420 · Phase 3 · registry result, not featured evidence · combination —Trastuzumab (AryoTrust) NCT03425656 · Phase 3 · registry result, not featured evidence —Trastuzumab (AryoTrust) / ACTH NCT03425656 · Phase 3 · registry result, not featured evidence · combination — NCT02472964 · Phase 3 · registry result, not featured evidence · combination 6.7%Trastuzumab (SID) NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (SID) Adjuvant NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (SID) Neoadjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 9.1%Trastuzumab (Vial) NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (Vial): Adjuvant NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (Vial): Neoadjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 2.8%AC Followed by Docetaxel + Hercept NCT00021255 · Phase 3 · registry result, not featured evidence · combination 1.7%Docetaxel + Carboplatin + Hercepti NCT00021255 · Phase 3 · registry result, not featured evidence · combination —Docetaxel 100 mg/m^2 Plus Bevacizu NCT00333775 · Phase 3 · registry result, not featured evidence · combination —Docetaxel 100 mg/m^2 Plus Bevacizu NCT00333775 · Phase 3 · registry result, not featured evidence · combination 28.4% NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1%Cohort A: ddAC, Paclitaxel, Pertuz NCT02132949 · Phase 2 · registry result, not featured evidence · combination 0.5%Cohort B: FEC, Docetaxel, Pertuzum NCT02132949 · Phase 2 · registry result, not featured evidence · combination — NCT01446016 · Phase 2 · registry result, not featured evidence · combination — NCT01527487 · Phase 2 · registry result, not featured evidence · combination — NCT00068341 · Phase 2 · registry result, not featured evidence · combination — NCT00179309 · Phase 2 · registry result, not featured evidence · combination 12.8% NCT00054275 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 19.6%Trastuzumab With AC-TH Regimena NCT02419742 · Phase 4 · registry result, not featured evidence · combination show 31 more results17.3%Trastuzumab With TCH Regimen NCT02419742 · Phase 4 · registry result, not featured evidence · combination 59.6% NCT02445586 · Phase 4 · registry result, not featured evidence · combination —Lapatinib (LTax/L) NCT00667251 · Phase 3 · registry result, not featured evidence 32.9%Lapatinib (LTax/L) - All Participa NCT00667251 · Phase 3 · registry result, not featured evidence 17% NCT02586025 · Phase 3 · registry result, not featured evidence 24% NCT03084237 · Phase 3 · registry result, not featured evidence · combination 37.9% NCT00703326 · Phase 3 · registry result, not featured evidence · combination 37.3% NCT01572038 · Phase 3 · registry result, not featured evidence · combination 10.3% NCT02953340 · Phase 3 · registry result, not featured evidence · combination 18.3% NCT02643420 · Phase 3 · registry result, not featured evidence · combination —Trastuzumab (AryoTrust) NCT03425656 · Phase 3 · registry result, not featured evidence 0%Trastuzumab (AryoTrust) / ACTH NCT03425656 · Phase 3 · registry result, not featured evidence · combination 39.3% NCT02472964 · Phase 3 · registry result, not featured evidence · combination —Trastuzumab (SID) NCT01940497 · Phase 3 · registry result, not featured evidence 7.6%Trastuzumab (SID) Adjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 9.5%Trastuzumab (SID) Neoadjuvant NCT01940497 · Phase 3 · registry result, not featured evidence —Trastuzumab (Vial) NCT01940497 · Phase 3 · registry result, not featured evidence 5.3%Trastuzumab (Vial): Adjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 15%Trastuzumab (Vial): Neoadjuvant NCT01940497 · Phase 3 · registry result, not featured evidence 27.1%AC Followed by Docetaxel + Hercept NCT00021255 · Phase 3 · registry result, not featured evidence · combination 26.8%Docetaxel + Carboplatin + Hercepti NCT00021255 · Phase 3 · registry result, not featured evidence · combination 46%Docetaxel 100 mg/m^2 Plus Bevacizu NCT00333775 · Phase 3 · registry result, not featured evidence · combination 42.1%Docetaxel 100 mg/m^2 Plus Bevacizu NCT00333775 · Phase 3 · registry result, not featured evidence · combination 24.3% NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 28.1%Cohort A: ddAC, Paclitaxel, Pertuz NCT02132949 · Phase 2 · registry result, not featured evidence · combination 33.3%Cohort B: FEC, Docetaxel, Pertuzum NCT02132949 · Phase 2 · registry result, not featured evidence · combination 2.6% NCT01446016 · Phase 2 · registry result, not featured evidence · combination 7.4% NCT01527487 · Phase 2 · registry result, not featured evidence · combination 40% NCT00068341 · Phase 2 · registry result, not featured evidence · combination 12% NCT00179309 · Phase 2 · registry result, not featured evidence · combination 71.8% NCT00054275 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a leukopenia 39.3% urinary tract infection 25% anaemia 21.4% NCT02419742 · Phase 4 · registry result, not featured evidence · combination show 27 more resultsanaemia 51.9% thrombocytopenia 42.3% asthenia 23.1% NCT02419742 · Phase 4 · registry result, not featured evidence · combination diarrhoea 32.7% anaemia 15.4% fatigue 15.4% NCT02445586 · Phase 4 · registry result, not featured evidence · combination diarrhoea 77.6% fatigue 69.9% alopecia 65.8% NCT00667251 · Phase 3 · registry result, not featured evidence neutropenia 70.2% (placebo 66.4%) leukopenia 61.9% (placebo 60.9%) alopecia 52.8% (placebo 50.9%) NCT02586025 · Phase 3 · registry result, not featured evidence white blood cell count decreased 82.2% neutrophil count decreased 81.8% alopecia 55.7% NCT03084237 · Phase 3 · registry result, not featured evidence · combination alopecia 71.1% (placebo 73%) stomatitis 50.5% (placebo 30.9%) diarrhoea 43.4% (placebo 39.8%) NCT00703326 · Phase 3 · registry result, not featured evidence · combination diarrhoea 67.8% alopecia 48.3% nausea 35.7% NCT01572038 · Phase 3 · registry result, not featured evidence · combination nausea 42.7% bone pain 40.2% lymphocyte count decreased 37.6% NCT02953340 · Phase 3 · registry result, not featured evidence · combination fatigue 60.9% nausea 56.9% alopecia 48.2% NCT02643420 · Phase 3 · registry result, not featured evidence · combination alopecia 48.1% anaemia 24.1% blood alkaline phosphatase increased 5.6% NCT03425656 · Phase 3 · registry result, not featured evidence · combination alopecia 57.9% neutropenia 36.8% asthenia 23.1% NCT02472964 · Phase 3 · registry result, not featured evidence · combination arthralgia 30.4% paraesthesia 27.2% asthenia 21.7% NCT01940497 · Phase 3 · registry result, not featured evidence asthenia 33.3% diarrhoea 28.6% arthralgia 23.8% NCT01940497 · Phase 3 · registry result, not featured evidence paraesthesia 51.6% asthenia 33.7% arthralgia 30.5% NCT01940497 · Phase 3 · registry result, not featured evidence hot flush 25% hypertension 25% arthralgia 20% NCT01940497 · Phase 3 · registry result, not featured evidence alopecia 98.5% nausea 87.9% asthenia 84.1% NCT00021255 · Phase 3 · registry result, not featured evidence · combination alopecia 96.4% asthenia 83.1% nausea 81.7% NCT00021255 · Phase 3 · registry result, not featured evidence · combination alopecia 70.1% (placebo 71%) diarrhoea 53.6% (placebo 48.8%) nausea 50.6% (placebo 53.9%) NCT00333775 · Phase 3 · registry result, not featured evidence · combination alopecia 71.8% (placebo 71%) diarrhoea 56.7% (placebo 48.8%) stomatitis 50.4% (placebo 27.6%) NCT00333775 · Phase 3 · registry result, not featured evidence · combination palmar-plantar erythrodysaesthesia syndrome 57.1% fatigue 53.1% nausea 52.2% NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 nausea 72.4% diarrhoea 71.9% alopecia 63.8% NCT02132949 · Phase 2 · registry result, not featured evidence · combination nausea 71.7% diarrhoea 71.2% alopecia 59.1% NCT02132949 · Phase 2 · registry result, not featured evidence · combination fatigue 5.3% back pain 2.6% dehydration 2.6% NCT01446016 · Phase 2 · registry result, not featured evidence · combination fatigue 74.1% nausea 61.1% alopecia 59.3% NCT01527487 · Phase 2 · registry result, not featured evidence · combination anemia 86.7% leukopenia 86.7% nausea 86.7% NCT00068341 · Phase 2 · registry result, not featured evidence · combination injection site reaction 68% fatigue 64% alopecia 60% NCT00179309 · Phase 2 · registry result, not featured evidence · combination fatigue 94.9% anemia 71.8% anorexia 71.8% NCT00054275 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Docetaxel
show 5 more results
show 9 more results
show 3 more results
show 19 more results
show 23 more results
show 1 more result
show 5 more results
show 1 more result
show 1 more result
show 3 more results
show 1 more result
+ 223 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Docetaxel's landscape · Ixabepilone's landscape